|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
|
20632082 |
2010 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PGE(2) significantly increased CYP1B1 protein and messenger RNA expression and dose dependently enhanced CYP1B1 promoter activity in human breast cancer MCF-7 cells.
|
20093341 |
2010 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our previous study demonstrated that chrysoeriol, which is a dietary methoxyflavonoid, selectively inhibited CYP1B1 enzymatic activity and might protect the CYP1B1 related-diseases such as breast cancer.
|
20553787 |
2010 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results demonstrate that CYP1B1 wild type in combination with COMT heterozygous or their inverse combination offer protection against breast cancer in premenopausal Indian women.
|
20037207 |
2009 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Assuming a recessive model, the minor allele of CYP1B1 V432L significantly increased the dose-response relationship between personal diagnostic X-ray exposure and breast cancer risk, adjusted for cumulative occupational radiation dose (p (interaction) = 0.03) and had a similar joint effect for cumulative occupational radiation dose adjusted for personal diagnostic X-ray exposure (p (interaction) = 0.06).
|
19214745 |
2009 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Results suggest that genetic variation in CYP1B1 has at most a minor influence on breast cancer susceptibility among Caucasian women.
|
19293312 |
2009 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although we found no significant association in the three populations combined, subgroup analyses revealed statistically significant associations of CYP1A2*1F in NJB, and CYP1B1 Leu(432)Val and CYP3A5*3 in JJ with breast cancer risk.
|
19229255 |
2009 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytochrome P450 (CYP) 1A1 and CYP1B1 are inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin) in the human breast cancer cell line, MCF-7.
|
18842620 |
2009 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
With the exception of GSTP1 and possibly CYP1B1*2, our findings do not provide support for the role of genetic variation in the catechol estrogen metabolism pathway and breast cancer risk in postmenopausal women.
|
19383894 |
2009 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Risk of breast cancer increased little with increasing years of E+P use among women with at least one CYP1B1 Val(432) allele; a large increase in risk was seen among women homozygous for CYP1B1 Leu(432).
|
18628428 |
2008 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
If confirmed in independent cohorts CYP1B1*3 may prove to be an important factor that helps to differentiate between paclitaxel-sensitive and resistant breast cancer patients.
|
18597657 |
2008 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the CYP1B1_1358_A>G polymorphism has an impact on ERalpha status in breast cancer in that the CYP1B1_1358_GG genotype known to encode higher CYP1B1 activity is associated with ERalpha negativity.
|
17922187 |
2008 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the cytochrome P450 1B1 (CYP1B1) and glutathione S-transferase (GST) drug metabolic enzymes, which are responsible for metabolic activation/detoxification of estrogen and environmental carcinogens, were analyzed for their association with breast cancer risk in 541 cases and 635 controls from a North Carolina population.
|
18425393 |
2008 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the CYP1B1 polymorphism may be an important modifier of breast cancer risk in Finnish Caucasian women who have been exposed to tobacco smoke and/or carry the NAT2 slow acetylator genotype.
|
17063266 |
2007 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
The scFv-QCM biosensors showed excellent sensitivity (detection limit, 2.2 +/- 0.9 nM) and specificity with a dissociation constant K(d) = (1.54 +/- 0.59) x 10(-7) M. CYP1B1 were quantitatively detected in normal and malignant cell lysates (e.g., human T47D breast cancer cell microsomes).
|
17297925 |
2007 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CYP1B1 gene appears to influence breast cancer susceptibility in Poland.
|
17458695 |
2007 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined associations between polymorphisms in genes related to estrogen metabolism (CYP1B1 codon 432G --> C rs#1056836, CYP1B1 codon 453A --> G rs#1800440, COMT codon 158G --> A rs#4680) and biosynthesis (CYP17 T --> C promoter rs#743572, CYP19 exon 4 TTTA repeat) and urinary estrogen metabolites (2-hydroxyestrogens (2-OHE), 16alpha-hydroxyestrone (16alpha-OHE1), and their ratio) in a pilot study of 64 pre- and post-menopausal women with a family history of breast cancer.
|
16850246 |
2007 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results support the hypothesis that the formation and accumulation of catechol estrogens in breast tissue through increased CYP1B1 expression and reduced COMT expression may play a significant role in breast cancer risk.
|
17507616 |
2007 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No association between the CYP1B1 Val432Leu polymorphism and breast cancer was observed in Asians (for Val/Val and Val/Leu combined, odds ratio (OR) = 1.0, 95% confidence interval (CI): 0.8, 1.2).
|
17053044 |
2007 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alternatively, the role of CYP1B1 in estrogen metabolism may influence the risk of invasive or paclitaxel resistant breast cancer in patients carrying the CYP1B1*3 allele.
|
17224914 |
2007 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Compared to the reference wild-type genotypes, marginally significant associations with the development of breast cancer were observed between carriers of the variant ESR1 - 104062T allele (OR 0.70, 95% CI 0.45, 1.09), the variant ESR2 *38A allele (OR 1.40; 95% CI 0.88, 2.25), and the variant CYP1B1 453Ser allele (OR 1.48, 95% CI 0.95, 2.32).
|
16808847 |
2006 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, common mutations/variants in the 3 genes BRCA1, NOD2 and CYP1B1, known to be associated with early-onset breast cancer, were assessed to determine their frequency in 348 unselected laryngeal cancers.
|
16331346 |
2006 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation of Cytochrome P450 1B1 (CYP1B1) and risk of breast cancer among Polish women.
|
16847423 |
2006 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we examined the expression of CYPs (CYP2A6, CYP1B1 and CYP3A) and p53 in specimens from 34 Japanese patients with breast cancer by immunohistochemistry.
|
15769614 |
2005 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |